These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30211730)

  • 1. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
    Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
    Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
    Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
    Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study.
    Walton KE; Garfield EM; Zhang B; Quan VL; Shi K; Mohan LS; Haugh AM; VandenBoom T; Yazdan P; Isales MC; Panah E; Gerami P
    J Am Acad Dermatol; 2019 Mar; 80(3):685-693. PubMed ID: 30287318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
    Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
    Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
    Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
    Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
    J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms.
    Boutko A; Asadbeigi S; Roth A; Lampley N; Olivares S; Dittmann D; Dittmann D; Jennings L; Gerami P
    Am J Dermatopathol; 2023 May; 45(5):289-299. PubMed ID: 36898007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients.
    Manrique-Silva E; David ME; Maider AM; García-Casado Z; Moro R; Requena C; Través V; Virós A; Kumar R; Nagore E
    Pigment Cell Melanoma Res; 2024 May; 37(3):343-351. PubMed ID: 38153178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
    Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
    Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
    Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi.
    Gerami P; Beilfuss B; Haghighat Z; Fang Y; Jhanwar S; Busam KJ
    J Cutan Pathol; 2011 Apr; 38(4):329-34. PubMed ID: 21323721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization (FISH) analysis of melanocytic nevi and melanomas: sensitivity, specificity, and lack of association with sentinel node status.
    Fang Y; Dusza S; Jhanwar S; Busam KJ
    Int J Surg Pathol; 2012 Oct; 20(5):434-40. PubMed ID: 22561674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Genomic Profiling of Melanocytic Nevi.
    Colebatch AJ; Ferguson P; Newell F; Kazakoff SH; Witkowski T; Dobrovic A; Johansson PA; Saw RPM; Stretch JR; McArthur GA; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Waddell N; Scolyer RA; Wilmott JS
    J Invest Dermatol; 2019 Aug; 139(8):1762-1768. PubMed ID: 30772300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutation is uncommon in acral lentiginous melanoma.
    Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
    J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
    Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
    Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
    Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
    J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    Fan Y; Lee S; Wu G; Easton J; Yergeau D; Dummer R; Vogel P; Kirkwood JM; Barnhill RL; Pappo A; Bahrami A
    J Invest Dermatol; 2016 Jan; 136(1):339-342. PubMed ID: 26763461
    [No Abstract]   [Full Text] [Related]  

  • 19. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors.
    Al-Rohil RN; Curry JL; Torres-Cabala CA; Nagarajan P; Ivan D; Aung PP; Lyons GF; Bassett RL; Prieto VG; Tetzlaff MT
    Hum Pathol; 2016 Jul; 53():73-81. PubMed ID: 27004944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
    Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.